New combo aims to tame HPV throat cancer with fewer side effects
Disease control
Not yet recruiting
This early-phase trial tests whether a new drug (ATRN-119) combined with a single, precise dose of radiation to the neck can safely and effectively treat early-stage HPV-positive throat cancer before surgery. About 35 participants will take the drug daily for 10 days and receive …
Phase: PHASE1, PHASE2 • Sponsor: John Lukens • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC